Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vipin Ramprasad Lohiya (NPI 1013295922)

Field	Value
Entity Type	Individual
Organization	Vipin Ramprasad Lohiya
Address	1267 Highway 54 W Ste 4200
City	Fayetteville
State	GA
ZIP	30214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 26, 2011

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s Medicare-centric footprint is pronounced: total Medicare revenue is $2.3M and there is no Medicaid billing on file, so the practice operates effectively as a single-payer (Medicare) billing entity in the available data. Analysts should treat Medicare patterns as the primary source of commercial scale and operational insight for this NPI.

Revenue is extremely concentrated in a small set of drug and visit lines: the precomputed top three Medicare codes account for 83.4% of the provider’s Medicare revenue, with J9271 alone contributing $1.4M (64.0%), J0897 contributing $364K (16.1%), and 99214 contributing $74.3K (3.3%). This concentration indicates that a handful of high-cost drugs dominate the revenue profile rather than a broad mix of office-based E/M services.

The code mix and top revenue drivers point to a hematology/oncology practice focused on high-volume infusion and biologic therapy administration: J9271 (pembrolizumab) and J0897 (denosumab) dominate receipts, and chemotherapy administration codes such as 96413, 96409, 96411, and 96417 also appear in the top lines. Together, these patterns are consistent with an infusion-centric operation that provides systemic cancer therapies and supportive biologics rather than a primarily procedural or diagnostic clinic.

On competitive standing, the provider is a high-volume national participant for key biologics: J9271 ranks #60 of 1841 providers nationally (97th percentile; notably above typical national volume) and J0897 ranks #285 of 10057 providers nationally (97th percentile; notably above typical national volume). These rankings suggest the provider is among the more active prescribers/administrators of these agents at a national scale, which may reflect a busy infusion practice or a referral hub for these drugs.

Several administration and ancillary infusion codes also show elevated positioning relative to peers and highlight operational scale: G0498 (chemotherapy initiation/continuation with portable pump) is an extreme outlier at rank #16 of 896 providers nationally (98th percentile; extreme outlier), and 96409 is high at rank #9 of 202 (96th percentile; typical, unremarkable volume by label but high relative rank). High placement on these administration codes supports the inference of mature infusion workflows and substantial clinic-based or coordinated home-infusion activity.

Despite drug revenue dominance, office E/M activity is present at above-average levels: 99214 has 782 claims, $95 avg paid/claim, $74.3K revenue and ranks #20616 of 479517 providers nationally (96th percentile; notably above typical national volume). This indicates regular follow-up visits and clinical management encounters that accompany the infusion business, though these visits represent a modest share of total Medicare revenue compared with the top drugs.

The claim-level detail shows very large claim counts for some codes, which clarifies operational throughput: J9271 has 35.2K claims and J1442 (filgrastim) has 20.5K claims, even where the average paid per claim is low for some line items (for example J1442 at $1 avg paid/claim). High claim volumes combined with varying per-claim values suggest billing by small dose units or frequent, recurring administrations rather than isolated high-dollar procedures.

The provider’s NPI tenure is longstanding—enumerated on 2011-07-26 (~15 years ago)—indicating an established presence in the market; combined with the high national ranks on several infusion and drug codes, this suggests a stable, operationally mature oncology infusion practice rather than a newly launched or transient operation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,200	$40	$1.4M
J0897	Injection, denosumab, 1 mg	20,220	$20	$364K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	780	$100	$74.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	650	$100	$65.3K
J1437	Injection, ferric derisomaltose, 10 mg	3,600	$20	$57.6K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	120	$340	$40K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	460	$80	$34.7K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	170	$170	$29.8K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	20,460	$1	$20.5K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	690	$20	$15.2K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Vipin Ramprasad Lohiya — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	40	15,200	$40	$767.3K
J0897	11	290	2,460	$20	$90.2K
J1437	10	30	2,850	$20	$56.4K
J2506	6	10	460	$80	$34.1K
J1454	3	20	80	$330	$25.9K
96413	8	160	170	$90	$20.3K
J1442	3	10	20,460	$1	$20K
J3490	3	50	50	$320	$19.8K
99214	645	13,640	120	$80	$17.8K
99233	2,659	3,880	90	$90	$13.9K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vipin Ramprasad Lohiya, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Vasileios Assikis	GA	Hematology & Oncology Physician	$3M	$0
Jonathan Bender	GA	Hematology & Oncology Physician	$2.6M	$0
Minesh Patel	GA	Hematology & Oncology Physician	$2.4M	$0
William Jonas	GA	Hematology & Oncology Physician	$1.8M	$0
Trevor Feinstein	GA	Hematology & Oncology Physician	$1.4M	$0
Jay Rhee	GA	Hematology & Oncology Physician	$871.7K	$0
Nikita Amin	GA	Hematology & Oncology Physician	$444.2K	$0

Nearby Providers

Other providers in the same ZIP code as Vipin Ramprasad Lohiya, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Summit Endoscopy Center	GA	Ambulatory Surgical Clinic/Center	$1.4M	$0
Board Of Commissioners Of Fayette County	GA	Land Ambulance	$693.7K	$224.7K
James Sandwich	GA	Dermatology Physician	$584.8K	$0
Georgia Urology Fayette Asc	GA	Ambulatory Surgical Clinic/Center	$504.4K	$0
Paul Feldman	GA	Plastic Surgery Physician	$483.9K	$0
Assured Care Ems LLC	GA	Land Ambulance	$457.1K	$0
Eye Consultants: Fayetteville Surgery Center	GA	Ophthalmology Physician	$449.7K	$0
Barbara Conlon	GA	Nurse Practitioner	$446.2K	$0
Pca Interventional Spine At Fayette, LLC	GA	Pain Clinic/Center	$434.5K	$0
Mobin Shah	GA	Hospitalist Physician	$380.8K	$0

Vipin Ramprasad Lohiya — Billing Profile & Reimbursement Data

Sign up for Vipin Ramprasad Lohiya — Billing Profile & Reimbursement Data policy alerts

Vipin Ramprasad Lohiya — Billing Profile & Reimbursement Data

Sign up for Vipin Ramprasad Lohiya — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References